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Abstract
Yohimbine is a prototypical alpha2-adrenergic receptor antagonist. Due to its relatively high 
selectivity, yohimbine is often used in experiments whose purpose is to examine the role of these 
receptors. For example, yohimbine has been employed at doses of 1–5 mg/kg to reinstate drug-
seeking behavior after extinction or to antagonize general anesthesia, an effects presumably being 
a consequence of blocking alpha2-adrenergic receptors. In this report we characterized dose-
dependent autonomic and behavioral effects of yohimbine and its interaction with an antagonist of 
5-HT1A receptors, WAY 100635. In low doses (0.5 – 2 mg/kg i.p.) yohimbine induced locomotor 
activation which was accompanied by a tachycardia and mild hypertension. Increasing the dose to 
3–4.5 mg/kg reversed the hypertension and locomotor activation and induced profound 
hypothermia. The hypothermia as well as the suppression of the locomotion and the hypertension 
could be reversed by the blockade of 5-HT1A receptors with WAY 100635. Our data confirm that 
yohimbine possesses 5-HT1A properties, and demonstrated that in doses above 1 mg/kg 
significantly activate these receptors.
1. INTRODUCTION
Yohimbine is a prototypical alpha-2 adrenoreceptor antagonist in neuropharmacological 
studies [16]. It was and still is widely used in various experimental studies in vitro [10, 19, 
34] and in vivo in conscious animals [3, 5, 7] and as an antagonist of general anesthesia [11, 
22, 24, 48].
Importantly, yohimbine has also been reported to evoke responses through dopaminergic 
[40], alpha1-adrenergic [13, 16], 5-HT1A [50, 51], and benzodiazepine [29] receptors. The 
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ability of yohimbine to act as a partial agonist for the human 5-HT1A receptor was 
demonstrated using receptors expressed in cell lines [1]. Hypothermia, induced by 
yohimbine in rats [21, 32] was linked to the activation of 5-HT1A receptors [32].
A major limitation of the above-referenced studies is that they do not provide data 
establishing the relative receptor selectivity of the doses of yohimbine employed in 
conscious animals. If yohimbine evokes some action in doses which are non-specific for 
alpha2-adrenoreceptors, then its pharmacological action needs to be interpreted with 
caution. For example, yohimbine–induced reinstatement of drug-seeking behavior is usually 
assumed to be alpha2-adrenoreceptor-mediated based on the widely known alpha2-blocking 
properties of the drug [2, 4]. However, alpha2-receptor antagonistRS-79948 did not trigger 
reinstatement despite it blocked effects of clonidine [46]. Also, in many studies yohimbine 
was used in high doses (1–5 mg/kg), which exceed those sufficient to block alpha2-
adrenoreceptors.
To determine the doses of yohimbine which significantly activate 5-HT1A receptors in 
conscious rats we studied dose-dependence of the effects of yohimbine and identified those 
mediated by 5-HT1A receptors by using WAY 100635, a specific antagonist of these 
receptors.
2. MATERIALS AND METHODS
2.1. Animal model
Male Sprague-Dawley rats (250–300 g) were used for all experiments. The animals were 
individually housed under standard controlled conditions (lights on 07:00–19:00, room 
temperature of 23–25°C) with free access to food and water. All procedures described were 
approved by the IACUC of the Indiana University School of Medicine and followed NIH 
guidelines.
Rats were implanted with telemetric transmitters (PXT, Transoma Med, St.Paul, MN) under 
isoflurane anesthesia as previously described [47]. After at least seven days of recovery, rats 
were brought to experimental room, placed on receivers of telemetric data acquisition 
system (LabPro 3.11, Data Sciences Int., St.Paul, MN) and allowed to adapt to experimental 
conditions. All animals for which data are reported remained in good health throughout the 
course of surgical procedures and experimental protocols as assessed by appearance, 
behavior, and maintenance of body weight.
2.2. Drugs
Yohimbine hydrochloride and WAY100635(WAY) were obtained from the Sigma-Aldrich 
(St. Louis, MO). WAY was dissolved in sterile saline. Yohimbine was first dissolved in an 
aliquot of distilled water under sonication, and then an equal volume of hypertonic saline 
(1.8% solution of NaCl in distilled water) was added.
2.3. Experimental Protocols
All injections were performed between 11:00 am and 2:00 pm to avoid the effect of 
circadian variability. Two experimental series were performed.
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In the first series of experiments, thermal, locomotor, and cardiovascular responses to 
various doses of yohimbine were studied. Five doses of yohimbine (0.5, 1, 2, 3, or 4.5 mg/kg 
in a volume of 1 ml/kg) or sterile saline were given i.p. Animals (N=4) received all doses of 
yohimbine in random order allowing two days between experiments.
In second series of experiments, three groups of rats (N=5 each) were prepared. Each rat was 
given two identical i.p. injections of either 0.5 or 3 mg/kg of yohimbine or vehicle separated 
by 2 days. Administration of yohimbine or saline was preceded by i.p. injection of either 
WAY (0.5 mg/kg in 1 ml/kg of saline) or saline. The selection of pretreatment for first trial 
was done by randomization. If in first trial the pretreatment was WAY, than pretreatment for 
the second trial was saline and vice versa.
2.4. Statistical analysis
The results are presented as the mean±SEM. For bar graphs and statistical comparisons we 
have averaged parameters between 15 and 30 min after injection of yohimbine, because this 
interval is close to maximal changes after both 0.5 and 3 mg/kg yohimbine. Baseline levels 
of activity, body temperature, heart rate (HR), and mean blood pressure (MBP) did not differ 
between groups across the series of experiments, so changes from baseline were analyzed 
unless specially noted.
Results were compared using a one way (series 1) or two-way (series 2) ANOVA with 
repeated measures followed by a Duncan post hoc test, where appropriate. A value of 
p<0.05 was considered to indicate a significant difference.
3. Results
Yohimbine dose-dependently affected all of the studied parameters: heart rate, blood 
pressure, body temperature, and locomotion (Fig. 1, locomotion F(5,18)=4.1; p=0.01; HR 
F(5,18)=7.8; p<0.001; MBP F(5,18)=5.9; p=0.002; temperature F(5,18)=21.5; p<0.001). In 
low doses (0.5 – 2 mg/kg i.p.) yohimbine induced locomotor activation accompanied by 
tachycardia, mild hypertension, and a trend to a hyperthermia (Fig. 1). In higher doses (3 
and 4.5 mg/kg) yohimbine reversed hypertension (Fig. 1C) and locomotor activation (Fig. 
1A) but not tachycardia (Fig. 1B). The trend to increasing body temperature visible after 0.5 
mg/kg was reversed by higher doses, and body temperature after 2 mg/kg was significantly 
lower than after 0.5 mg/kg, (Fig. 1D). In higher doses yohimbine induced dramatic 
hypothermia (Fig. 1D). Core body temperature fell to 34.7±0.6°C after 3 mg/kg yohimbine 
and to 33.4±0.9°C after 4.5 mg/kg yohimbine. The rates of decline in temperature between 5 
and 30 min were similar after 3 mg/kg and 4.5 mg/kg yohimbine (0.058±0.019°C/min vs 
0.058±0.004°C/min), but the nadir occurred later after the higher dose (59±14 min vs 
118±19 min). Dose-response curve for yohimbine for temperature had a clear sigmoidal 
shape with EC50 equal 2.2 mg/kg (95% confidence interval 1.8–2.6 mg/kg).
Pretreatment with WAY (0.5 mg/kg, i.p.) had effects on all parameters (locomotion 
F(1,12)=10.9; p<0.05; HR F(1,12)=50.4; p<0.001; MBP F(1,12)=19.0; p<0.001; 
temperature F(1,12)=64.7; p<0.001) and effect on temperature was also dependent on the 
dose of yohimbine (F(2,12)=18.0; p<0.001). Administration of WAY did not affect the 
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locomotor response to i.p. injection of saline or 0.5 mg/kg yohimbine, however it 
significantly increased locomotion after 3 mg/kg yohimbine (Fig. 2, A1–D1). 
Administration of WAY moderately increased (i.e., by approximately 50 beats/min) 
tachycardia seen in response to saline and both 0.5 and 3.0 mg/kg yohimbine (Fig 2, A2–
D2). Unlike heart rate, the effect of WAY on blood pressure changes induced by yohimbine 
was dependent on the dose of yohimbine (Fig. 2, A3–D3). Increase of blood pressure 
induced by 0.5 mg/kg yohimbine was modified not significantly by WAY, but pretreatment 
with the antagonist of 5-HT1A receptors clearly prevented a drop of blood pressure after 3 
mg/kg yohimbine (Fig. 2, C3–D3). Finally, the 5-HT1A antagonist slightly increased 
hyperthermic response to injections of saline or 0.5 mg/kg yohimbine (Fig. 2, A4–D4). 
However, administration of WAY completely abolished hypothermia evoked by 3 mg/kg 
yohimbine (Fig. 2, C4–D4).
4. Discussion
In many studies, in which yohimbine was used as a prototypical alpha2-adrenoblocker, 
doses of drug were significantly higher than required for specific effects of this compound 
on the alpha2-adrenoreceptor. Our data unequivocally demonstrated that high doses of 
yohimbine activate 5HT1A receptors.
Administration of yohimbine at high doses results in significant hypothermia, similar to 
decrease of body temperature evoked by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT), a prototypical 5-HT1A agonist [17]. Yohimbine-induced hypothermia is prevented 
by WAY (our data and [32]) in a dose specific for 5-HT1A blocking action [18]. Previously, 
we demonstrated that hypothermia evoked by systemic administration of the 8-OH-DPAT is 
mediated by activation of 5-HT1A receptors in the ventromedial medulla [39]. Most likely, 
the effect of systemically-administered yohimbine on core body temperature is also 
mediated by the inhibition of ventromedial medulla through activation of 5-HT1A receptors: 
the rate of cooling after high dose of yohimbine (0.06±0.02°C/min after 3 mg/kg yohimbine) 
is similar to one induced by inhibition of neuronal activity in ventromedial medulla [52].
What is the dose of yohimbine which can be clearly identified as evoking 5-HT1A effect, 
using body temperature as an experimental end-point? Administration of 3 mg/kg results in 
clear hypothermia. Considering that the slope of temperature decline after 3 mg/kg is similar 
to the one after 4.5 mg/kg, the effect of yohimbine on thermoregulation is saturated at 3 
mg/kg. The administration of 2 mg/kg results in significantly lower body temperature 
compared with lowest studied dose (0.5 mg/kg). In fact, if there is a progressive increase of 
hyperthermic action with increasing dose, then hypothermic effect of 1 mg/kg would simply 
be masked. Non-linear regression of dose-dependency of the hypothermic effects of 
yohimbine results in EC50 estimate of 2.2 mg/kg. Therefore, we conclude that in doses 
above 1 mg/kg yohimbine has considerable 5-HT1A agonistic activity when administered 
intraperitoneally. This estimation is supported by complete suppression of serotonergic 
neurons in the dorsal raphe nucleus by 0.5 mg/kg yohimbine intravenously, which could be 
reversed by WAY [32].
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The data in the National Institute of Mental Health – Psychoactive Drug Screening Program 
(NIMH-PDSP) database reveal, that in rats yohimbine is approximately 80-fold more 
selective for alpha-2 adrenergic receptors than to 5HT1A receptors. This selectivity 
corresponds to the ratio of doses needed to activate 5-HT1A receptors to doses required to 
block alpha2-adrenoreceptors in conscious rats. Is it possible that WAY blocks hypothermic 
effects of yohimbine through receptors other than 5-HT1A ? WAY does not affect alpha1-
adrenoreceptor-mediated responses in doses below 1 mg/kg [49], and the sensitivity of 
alpha2-adrenoreceptors to WAY is at least twice less than that of alpha1-adrenoreceptors 
(PDSP database). According to PDSP database the only other candidate receptor, to which 
both substances could bind with reasonable affinity, is the D2 receptor. However, the 
reported threshold dose in which WAY blocks effects on 5-HT1A is 6 µg/kg [35], and the 
ratio of Ki for WAY acting on two receptors exceeds 1000 (0.24 nM for 5-HT1A vs 370 nM 
for D2, PDSP), than the dose in this study (0.5 mg/kg) is not sufficient to block effects on 
D2.
Presence of 5-HT1A-mediated effects of yohimbine in doses higher than 1 mg/kg can be 
found using other experimental end-points. Yohimbine-induced locomotion after 0.5 mg/kg 
was not affected by WAY, while the effect of 3 mg/kg was augmented by WAY. 
Considering that the administration of 8-OH-DPAT, an agonist of 5-HT1A receptors, 
increases locomotion by itself [12, 14], but suppresses locomotion induced by other stimuli 
[8, 20], this double action can explain the relatively small locomotor responses to yohimbine 
[42] and its ability to suppress locomotion in behavioral paradigms [9].
In low doses yohimbine increased inferior cardiac nerve discharge [30] and caused 
tachycardia [25, 38]. However, in higher doses yohimbine inhibited nerve discharge, and 
this inhibition was reversed by spiperone [30], an agent with 5-HT1A-antagonist properties 
[28]. Similarly, we found that high dose of yohimbine caused the reversal of hypertonic 
response, and this reversal was completely prevented by pretreatment with WAY. 
Yohimbine has also other effects typical for 5-HT1A agonists, such as release of ACTH and 
corticosterone [36], which was observed in rats only in doses higher than 1 mg/kg [45].
There are accumulating data on the importance of 5-HT1A agonistic properties of 
yohimbine in experimental studies. Yohimbine (2.5–7.5 mg/kg) disrupted prepulse 
inhibition [37] and produced antinociception [43] in rats via the action at 5-HT1A receptors 
but not at alpha2-adrenoceptors. Ability of alpha2-adrenoblockers to affect 5-HT1A 
receptors is not unique for yohimbine: BRL-44408 recognizes 5-HT1A receptors along with 
being alpha2-adrenoceptor antagonist [31].
Understanding dose-dependence of effects of yohimbine mediated by different receptors has 
a potential to affect interpretation of various phenomena related to the use of this drug. 
Yohimbine is known to reinstate methamphetamine [44], cocaine [15, 27], and alcohol 
seeking [26] behaviors, and it is assumed that these actions result from a blockade of alpha2-
adrenoceptors [4, 26]. However, the doses of yohimbine in all these studies (1.25–5 mg/kg) 
appear to be sufficient to activate 5-HT1A receptors, while a dose less than 1 mg/kg was not 
effective in reinstating food-seeking behavior [33]. Considering that yohimbine is quickly 
accumulated in the brain but is eliminated with t1/2 of 7.7 h [23], the need to use high doses 
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cannot be justified by pharmacokinetics. A potential role of 5-HT1A receptors is supported 
by the ability of WAY to attenuate cocaine-induced reinstatement [6, 41].
Similarly, an antagonism of general anesthesia in rats also requires 1–2 mg/kg of yohimbine 
[22], while 0.25 mg/kg of yohimbine did not reverse the anesthesia in cats [48]. We 
conclude that in the doses, in which it is used in many experimental paradigms, yohimbine is 
also a 5-HT1A agonist.
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Highlights
• Alpha2-adrenoblocking properties of yohimbine are observed in doses below 1 
mg/kg.
• In doses exceeding 1 mg/kg yohimbine is a 5-HT1A-agonist.
• Yohimbine reinstates drug-seeking behavior or antagonizes general anesthesia 
in high doses (more than 1 mg/kg).
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Figure 1. 
Physiological responses to intraperitoneal injection of saline or various doses of yohimbine. 
The data are averages of locomotor activity (A), heart rate (B), mean blood pressure (C) and 
body temperature (D) over interval of 15–30 minutes after injection. * - significant 
difference from saline (p<0.05). # - significant difference from the lowest dose (0.5 mg/kg, 
p<0.05).
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Figure 2. 
Physiological responses to intraperitoneal injection of saline or WAY (0.5 mg/kg, i.p.) at 
time 0 followed by i.p. injection of saline or yohimbine (0.5 mg/kg or 3 mg/kg) at 5 min. 
The bar graphs (right column) show the averages of locomotor activity, cardiovascular 
parameters and core body temperature during the interval of 15–30 min after injection of 
yohimbine.
* - significant difference from saline pretreatment (p<0.05).
Zaretsky et al. Page 12
Neurosci Lett. Author manuscript; available in PMC 2016 October 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
